The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Haematological manifestations of lupus
Open accessAbstract
Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus
Matsuyama, W., Yamamoto, M., Higashimoto, I., Oonakahara, K.-I., Watanabe, M., Machida, K., Yoshimura, T., Eiraku, N., Kawabata, M., Osame, M., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4274 · Cited by 74
RetractedThe 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., & Spasoff, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250604 · Cited by 1,920
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
Tsai, H.-M., & Lian, E. C.-Y. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392203 · Cited by 1,760
Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P. A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392202 · Cited by 1,657
Love, P. E., & Santoro, S. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-682 · Cited by 1,095
SYSTEMIC LUPUS ERYTHEMATOSUS: REVIEW OF THE LITERATURE AND CLINICAL ANALYSIS OF 138 CASES
HARVEY, A. M., SHULMAN, L. E., TUMULTY, P. A., CONLEY, C. L., & SCHOENRICH, E. H. (1954) · Medicine · doi:10.1097/00005792-195412000-00001 · Cited by 993
Cited by
Jung, J.-H., Soh, M.-S., Ahn, Y.-H., Um, Y.-J., Jung, J.-Y., Suh, C.-H., & Kim, H.-A. (2016) · Medicine · doi:10.1097/md.0000000000002818 · Cited by 82
Metadata
- Authors
- Fayyaz, A., Igoe, A., Kurien, B. T., Danda, D., James, J. A., Stafford, H. A., & Scofield, R. H.
- Venue
- Lupus Science & Medicine
- Publisher
- BMJ
- Published
- 2015-03
- Volume
- 2
- Issue
- 1
- Pages
- e000078
- ISSN
- 2053-8790 (ISSN-L)
- OpenAlex
- W2137101896
- Cited by
- 294
- References
- 71
- FWCI
- 12.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Haematological manifestations of lupus. https://app.cochat.ai/papers/10.1136/lupus-2014-000078
- The paper
- Fayyaz, A., Igoe, A., Kurien, B. T., Danda, D., James, J. A., Stafford, H. A., & Scofield, R. H. (2015). Haematological manifestations of lupus. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2014-000078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.